SCHEMBL6764398

SCHEMBL6764398

CCNc1cc(N(C)C)nc(NCC)[n+]1[O-]

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DNM2 P50570 1/20 0.33
NUDT1 P36639 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768499 0.84 DNM2 (0.38) DNM2
SCHEMBL8599872 0.83 NUDT1 (0.36) DNM2NUDT1
SCHEMBL8599974 0.71 DNM2 (0.37) DNM2NUDT1
SCHEMBL6404443 0.71 DNM2 (0.37) DNM2NUDT1
SCHEMBL7518385 0.69 DNM2 (0.44) DNM2NUDT1
SCHEMBL7712163 0.63 DNM2 (0.47) DNM2NUDT1
SCHEMBL8599188 0.62 KMT2A (0.33)
SCHEMBL9182270 0.61 NUDT1 (0.66) DNM2NUDT1
SCHEMBL7633778 0.60 PGK1 (0.36)
SCHEMBL8598479 0.60 NUDT1 (0.36) NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020103216-A1 Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide PRUCHE FRANCIS (FR) 2002-08-01 US claimed
EP-0829260-B1 Use of at least one pyrimidine derivative substituted in position 6 as stimulant of tyrosinase OREAL (FR) 2002-05-15 EP claimed
US-6380263-B1 ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR SOCIETE L'OREAL (FR) 2002-04-30 US claimed
US-6726940-B2 STIMULATING MELANOGENESIS. SOCIETE L'OREAL S.A. (FR) 2004-04-27 US disclosed
US-20020122812-A1 Use of at least one extract of the genus chrysanthemum for assisting skin and/or hair pigmentation MARTIN RICHARD (FR) 2002-09-05 US disclosed
US-20020103216-A1 Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide PRUCHE FRANCIS (FR) 2002-08-01 US disclosed
US-6380263-B1 ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR SOCIETE L'OREAL (FR) 2002-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020122812-A1 Use of at least one extract of the genus chrysanthemum for assisting skin and/or hair pigmentation TYR, CUTA, MC1R DNM2 2271/4885NUDT1 3616/4885
US-20020103216-A1 Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide TYR, TH, MC1R DNM2 3991/4885NUDT1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.